Antineutrophil cytoplasmic antibody-associated vasculitides are usually treated with a combination of high-dose corticosteroids and cyclophosphamide therapy to induce remission, commonly followed by maintenance treatment with a less-toxic immunosuppressant. Azathioprine and methotrexate are both options for maintenance therapy, but whether one of these immunosuppressants is superior to the other is unclear.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790–2803 (2008).
Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621–631 (2005).
Pagnoux, C. et al. Predictors of treatment resistance and relapse in ANCA small vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908–2918 (2008).
Salama, A. D., Ryba, M., Levy, J., Pusey, C. D. & Gaskin, G. 30 year follow up of 400 patients with ANCA associated vasculitis: predictors of relapse and survival. J. Am. Soc. Nephrol. 17, 732A (2006).
Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36–44 (2003).
De Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461–2469 (2005).
Metzler, C. et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46, 1087–1091 (2007).
Stegeman, C. A., Tervaert, J. W., de Jong, P. E. & Kallenberg, C. G. Trimethoprim–sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 335, 16–20 (1996).
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351–361 (2005).
Koukoulaki, M. & Jayne, D. R. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin. Pract. 102, c100–c107 (2006).
Jones, R., Walsh, M. & Jayne, D. for the European Vasculitis Study Group. Randomised Trial of Rituximab Versus Cyclophosphamide for ANCA Associated Renal Vasculitis: RITUXVAS. J. Am. Soc. Nephrol. 19, 61A (2008).
Rituximab for the treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (RAVE) http://clinicaltrials.gov/ct2/show/NCT00104299.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Nachman, P. Which maintenance therapy for ANCA vasculitis?. Nat Rev Nephrol 5, 254–256 (2009). https://doi.org/10.1038/nrneph.2009.52
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.52
